Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$24.3 million.

  • Aligos Therapeutics' Cash from Operations fell 2111.34% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.2 million, marking a year-over-year increase of 686.72%. This contributed to the annual value of -$80.7 million for FY2024, which is 221.02% down from last year.
  • Aligos Therapeutics' Cash from Operations amounted to -$24.3 million in Q3 2025, which was down 2111.34% from -$15.5 million recorded in Q2 2025.
  • Aligos Therapeutics' 5-year Cash from Operations high stood at -$13.6 million for Q2 2023, and its period low was -$37.5 million during Q4 2021.
  • Over the past 5 years, Aligos Therapeutics' median Cash from Operations value was -$20.9 million (recorded in 2025), while the average stood at -$21.9 million.
  • As far as peak fluctuations go, Aligos Therapeutics' Cash from Operations skyrocketed by 5522.15% in 2022, and later plummeted by 4316.25% in 2024.
  • Over the past 5 years, Aligos Therapeutics' Cash from Operations (Quarter) stood at -$37.5 million in 2021, then skyrocketed by 55.22% to -$16.8 million in 2022, then plummeted by 35.01% to -$22.7 million in 2023, then grew by 18.78% to -$18.4 million in 2024, then plummeted by 32.29% to -$24.3 million in 2025.
  • Its last three reported values are -$24.3 million in Q3 2025, -$15.5 million for Q2 2025, and -$20.9 million during Q1 2025.